enow.com Web Search

  1. Ads

    related to: prostate cancer castration resistant treatment reviews

Search results

  1. Results from the WOW.Com Content Network
  2. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.

  3. Comparison of bicalutamide with other antiandrogens

    en.wikipedia.org/wiki/Comparison_of_bicalutamide...

    Bicalutamide monotherapy has been reported to be roughly equivalent in effectiveness compared to GnRH analogues and castration in the treatment of prostate cancer. [ 4 ] [ 78 ] [ 82 ] A meta-analysis concluded that there is a slight effectiveness advantage for GnRH analogues/castration, but the differences trended towards but did not reach ...

  4. Darolutamide - Wikipedia

    en.wikipedia.org/wiki/Darolutamide

    Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [8] [4] [5] [9] [10] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. [4]

  5. Enzalutamide - Wikipedia

    en.wikipedia.org/wiki/Enzalutamide

    Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...

  6. Medical uses of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

    Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

  7. Tasquinimod - Wikipedia

    en.wikipedia.org/wiki/Tasquinimod

    Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant ...

  1. Ads

    related to: prostate cancer castration resistant treatment reviews